Grunenthal, Purdue sign licensing agreement for certain intellectual property rights

The intellectual property rights will be leveraged in the development of an abuse-deterrent formulation technology for extended-release morphine sulfate.

Grunenthal CEO Harald Stock said, "This is certainly another achievement that exemplifies our expertise, strength and innovative power in developing abuse deterrent technologies and tamper resistant formulations."

In order to tackle the serious and complex public health issue, Grunenthal seeks to focus on conducting research and development of tamper resistant formulation technologies to mitigate the abuse of prescription medicines.